{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:50:34Z","timestamp":1773363034030,"version":"3.50.1"},"reference-count":143,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/13543784.2023.2242767","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T01:46:14Z","timestamp":1690595174000},"page":"583-600","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Psoriasis: a focus on upcoming oral formulations"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-7756","authenticated-orcid":false,"given":"Llu\u00eds","family":"Rusi\u00f1ol","sequence":"first","affiliation":[{"name":"Dermatology Department IIB Sant Pau, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-3593","authenticated-orcid":false,"given":"Elena","family":"Carmona-Rocha","sequence":"additional","affiliation":[{"name":"Dermatology Department IIB Sant Pau, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[{"name":"Dermatology Department IIB Sant Pau, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S294173"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0205-2"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16746"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2021.00028"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090480"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1261"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1254"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001227"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6621"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207577200"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.011"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.08.001"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03188-w"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93396"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.021"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.340"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2021.03.012"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2020.12.006"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401867"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S380686"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140280"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90105-L"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00347-w"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14585"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400205"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519847414"},{"key":"e_1_3_5_43_1","first-page":"55","article-title":"Review on novel oral therapies for psoriasis","volume":"14","author":"Marushchak O","year":"2021","unstructured":"Marushchak O, Yakubov R, Yakubov R, et al. Review on novel oral therapies for psoriasis. J Clin Aesthet Dermatol. 2021;14:55\u201363. Internet Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35096256","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.053"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.040"},{"key":"e_1_3_5_50_1","unstructured":"Reuters Staff. FDA declines to expand approval of Pfizer arthritis drug [Internet]. OCTOBER 14 2015. 2015 [cited 2023 May 24]. Available from: https:\/\/www.reuters.com\/article\/pfizer-psoriasis-fda-idUSL1N12E2OW20151014."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2016.12.001"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13745"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14399"},{"key":"e_1_3_5_54_1","article-title":"U.S. FDA approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for adults with moderate-to-severe atopic dermatitis","author":"Pfizer","year":"2022","unstructured":"Pfizer. U.S. FDA approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for adults with moderate-to-severe atopic dermatitis. Pfizer. 2022.","journal-title":"Pfizer"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13612"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16004"},{"key":"e_1_3_5_57_1","unstructured":"Olumiant - European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. 2023."},{"key":"e_1_3_5_58_1","unstructured":"FDA approves OLUMIANT\u00ae (baricitinib) 2-mg tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis [Internet]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults. 2018 [cited 2023 May 24]. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults."},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.354"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1115819"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1046"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.03.962"},{"key":"e_1_3_5_65_1","unstructured":"Nick Paul Taylor. Pfizer sells midphase inflammatory drugs to mystery startup exiting race against Bristol Myers [Internet]. BIOTECH. 2021 [cited 2023 May 24]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/pfizer-sells-midphase-inflammatory-drugs-to-mystery-startup-exiting-race-against-bristol#:~:text=Biotech- Pfizer%20sells%20midphase%20inflammatory%20drugs%20to%20mystery exiting%20race%20against%20Bristol%20Myers&text=Pfizer%20is%20getting%20out%20of 25%25%20stake%20in%20the%20startup."},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30397-0"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12929"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_3_5_72_1","first-page":"8953","article-title":"Identification of N-Methyl nicotinamide and N-Methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2)","author":"Moslin R","year":"2019","unstructured":"Moslin R, Zhang Y, Wrobleski ST, et al. Identification of N-Methyl nicotinamide and N-Methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2). J Med Chem American Chemical Society. 2019. p. 8953\u20138972.","journal-title":"J Med Chem American Chemical Society"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.001"},{"key":"e_1_3_5_75_1","unstructured":"Gordon K Papp K Gooderham M et al. BMS-986165 an oral selective tyrosine kinase 2 (TYK2) inhibitor: evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis patients [Internet]. Available from: https:\/\/ctep.cancer.gov\/."},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00649-y"},{"key":"e_1_3_5_78_1","unstructured":"Blankenship K. Celgene say goodbye to Otezla: BMS agrees to sell psoriasis drug to clear $74B merger [Internet]. FIERCE Pharma. 2019 [cited 2023 May 7]. Available from: https:\/\/www.fiercepharma.com\/pharma\/say-goodbye-to-otezla-bms-agress-to-sell-psoriasis-med-as-part-celgene-merger-deal."},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y"},{"key":"e_1_3_5_82_1","unstructured":"Sotyktu; Deucravacitinib. European medicines agency approval [Internet]. EMA. 2023 [cited 2023 May 7]. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-sotyktu_en.pdf."},{"key":"e_1_3_5_83_1","unstructured":"Bristol Myers Squibb receives European commission approval of sotyktu (deucravacitinib) a once-daily oral treatment for adults with moderate-to-severe plaque psoriasis [internet]. Bristol Myers Squibb. 2023 [cited 2023 May 7]. Available from: https:\/\/news.bms.com\/news\/corporate-financial\/2023\/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Sotyktu-deucravacitinib-a-Once-Daily-Oral-Treatment-for-Adults-With-Moderate-to-Severe-Plaque-Psoriasis\/default.aspx."},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_3_5_85_1","first-page":"6","article-title":"Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC Study","volume":"18","author":"Rubin DT","year":"2022","unstructured":"Rubin DT. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC Study. Gastroenterol Hepatol (N Y). 2022;18:6. InternetAvailable from. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36756651","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01698"},{"key":"e_1_3_5_87_1","unstructured":"Takeda. Takeda to acquire late-stage potential best-in-class oral allosteric TYK2 Inhibitor NDI-034858 from Nimbus therapeutics [Internet]. Takeda. 2022 [cited 2023 Jun 5]. Available from: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2022\/takeda-to-acquire-late-stage-potential-best-in-class-oral-allosteric-tyk2-inhibitor\u2013ndi-034858-from-nimbus-therapeutics\/."},{"key":"e_1_3_5_88_1","unstructured":"Takeda. Takeda announces positive results in phase 2b study of investigational TAK-279 an oral once-daily TYK2 inhibitor in people with moderate-to-severe plaque psoriasis [internet]. Takeda. 2023 [cited 2023 Jun 5]. Available from: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/takeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279\/."},{"key":"e_1_3_5_89_1","first-page":"105","article-title":"Otezla (apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis","volume":"8","author":"Fala L","year":"2015","unstructured":"Fala L. Otezla (apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8:105\u2013110. Internet Available from. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26629274","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18647"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18812"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00422"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18760-1"},{"key":"e_1_3_5_94_1","unstructured":"Armstrong M Elmhirst E Lilly\u2019s oral interleukin exit hints at a dicey future [Internet]. Evaluate Vantage. 2022 [cited 2023 May 8]. Available from: https:\/\/www.evaluate.com\/vantage\/articles\/news\/corporate-strategy\/lillys-oral-interleukin-exit-hints-dicey-future."},{"key":"e_1_3_5_95_1","article-title":"DICE Therapeutics announces positive topline data from phase 1 clinical trial of lead oral IL-17 antagonist, DC-806","author":"Budwick D","year":"2022","unstructured":"Budwick D. DICE Therapeutics announces positive topline data from phase 1 clinical trial of lead oral IL-17 antagonist, DC-806. For Psoriasis. 2022.","journal-title":"For Psoriasis"},{"key":"e_1_3_5_96_1","unstructured":"Protagonist therapeutics. protagonist reports positive results from phase 1 and pre-clinical studies of oral interleukin-23 receptor antagonist JNJ-2113 [Internet]. Protagonist Therapeutics Inc. 2023 [cited 2023 May 24]. Available from: https:\/\/www.prnewswire.com\/news-releases\/protagonist-reports-positive-results-from-phase-1-and-pre-clinical-studies-of-oral-interleukin-23-receptor-antagonist-jnj-2113-301823039.html."},{"key":"e_1_3_5_97_1","unstructured":"Bader K New positive results of oral IL-23 receptor antagonist for psoriasis [internet]. Dermatology Times. 2023 [cited 2023 May 24]. Available from: https:\/\/www.dermatologytimes.com\/view\/new-positive-results-of-oral-il-23-receptor-antagonist-for-psoriasis."},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.06.018"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20828-3"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13616-1"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1037983"},{"key":"e_1_3_5_102_1","article-title":"SAR-441566 by Sanofi for psoriasis: likelihood of approval","author":"Pharmaceutical Technology","year":"2023","unstructured":"Pharmaceutical Technology. SAR-441566 by Sanofi for psoriasis: likelihood of approval. Pharm Technol. 2023.","journal-title":"Pharm Technol"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1621\/nrs.07003"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01210"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030730"},{"key":"e_1_3_5_106_1","unstructured":"Vitae Pharmaceuticals I Vitae pharmaceuticals achieves proof-of-concept with first-in-class RORyt Inhibitor in moderate to severe psoriasis [Internet]. 2016 [cited 2023 May 24]. Available from: https:\/\/www.globenewswire.com\/news-release\/2016\/03\/16\/820582\/0\/en\/Vitae-Pharmaceuticals-Achieves-Proof-of-Concept-with-First-in-Class-RORyt-Inhibitor-in-Moderate-to-Severe-Psoriasis.html."},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1262350"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00588"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00348"},{"key":"e_1_3_5_110_1","unstructured":"The pharma letter. Aurigene\u2019s AUR101 disappoints in phase IIb study in moderate to severe psoriasis [Internet]. Thepharmaletter. 2022 [cited 2023 May 24]. Available from: https:\/\/www.thepharmaletter.com\/article\/aurigene-s-aur101-disappoints-in-phase-ii-study-in-moderate-to-severe-psoriasis."},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12948"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00167"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxz037"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708060-00002"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.11.015"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0179-3"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2014.993084"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60803-5"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S290309"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27123680"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2310970"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.8.729"},{"issue":"8","key":"e_1_3_5_123_1","first-page":"931","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from a phase II\/III multicenter, randomized, controlled trial","volume":"15","author":"David M","year":"2016","unstructured":"David M, Gospodinov DK, Gheorghe N, et al. Treatment of plaque-type psoriasis with oral CF101: data from a phase II\/III multicenter, randomized, controlled trial. J Drugs Dermatol. 2016;15(8):931\u2013938.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-020-00573-7"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2021.106210"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1838"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14302"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20880"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128897"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25061369"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01593-z"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.19"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414189111"},{"key":"e_1_3_5_134_1","first-page":"1937","volume-title":"Journal of the European Academy of Dermatology and Venereolog","author":"Zhang L","year":"2022","unstructured":"Zhang L, Guo L, Wang L, et al. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis \u2013 a network meta-analysis. Journal of the European Academy of Dermatology and Venereolog. John Wiley and Sons Inc; 2022. p. 1937\u20131946."},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-022-00287-7"},{"key":"e_1_3_5_136_1","unstructured":"Helfand C FDA swats down Pfizer\u2019s Xeljanz in plaque psoriasis [Internet]. Fierce Pharma. 2015 [cited 2023 May 24]. Available from: https:\/\/www.fiercepharma.com\/regulatory\/fda-swats-down-pfizer-s-xeljanz-plaque-psoriasis."},{"key":"e_1_3_5_137_1","unstructured":"Abbvie. RINVOQ\u00ae (upadacitinib) receives U.S. FDA approval for active psoriatic arthritis [internet]. Abbvie. 2021 [cited 2023 Jun 5]. Available from: https:\/\/news.abbvie.com\/news\/press-releases\/rinvoq-upadacitinib-receives-us-fda-approval-for-active-psoriatic-arthritis.htm."},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.696597"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-023-01257-2"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00903-5"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5845"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00703-1"},{"key":"e_1_3_5_143_1","first-page":"S19","article-title":"Interleukin-17 inhibitor combination therapies for the treatment of psoriasis: a systematic review","volume":"15","author":"Martin A","year":"2022","unstructured":"Martin A, Thatiparthi A, Liu J, et al. Interleukin-17 inhibitor combination therapies for the treatment of psoriasis: a systematic review. J Clin Aesthet Dermatol. 2022;15:S19\u2013S31. InternetAvailable from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35784449","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15759"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2242767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T07:02:31Z","timestamp":1710313351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2242767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":143,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/13543784.2023.2242767"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2242767","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}